Brand Name Justification (Naloxone Oral Syringes) KO Signed._Redacted.pdf

This document is a Memorandum for Record - Limiting Competition at or below the Simplified Acquisition Threshold for the BAMC Department of Pharmacy. The contract is for 1,413 naloxone oral syringes annually, with a base plus 4-year contract (5 years total), covering the period from 01 October 2025 to 30 September 2030. The purchase will be made via Purchase Order Number W81K0022P0048, with a fixed price contract type and funding from Operations & Maintenance, Army (OMA) and Other Funds: DHP for Fiscal Year 2026.

The naloxone prefilled syringes are an emergency treatment for people who have overdosed on opioids, with the critical purpose of quickly reversing the effects of opioid overdose and potentially saving lives. The document notes that competition is anticipated, and the contract is not a sole source requirement. The brand name of the syringes is specified, and the contract will be posted with the solicitation since it is a brand name restriction over $25K. The Contracting Officer has certified that the anticipated cost is fair and reasonable, and completing this purchase as a brand name is in the best interest of the Government.